Apelin receptor inhibition in ischemia-reperfused mouse hearts protected by endogenous n-3 polyunsaturated fatty acids

被引:1
|
作者
Zheng, Shuang [1 ]
Tan, Weijiang [1 ,2 ]
Li, Xiang [1 ,3 ]
Wang, Lijing [4 ]
Zhu, Caiyi [1 ]
Pyle, W. Glen [5 ,6 ]
Chen, Jianxin [2 ]
Wu, Jian [7 ]
Ren, Xuecong [1 ]
Chen, Honghua [1 ]
Zou, Yunzeng [3 ,7 ]
Backx, Peter H. [8 ]
Yang, Feng Hua [1 ]
机构
[1] Guangdong Lab Anim Monitoring Inst, Guangzhou, Peoples R China
[2] South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China
[3] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China
[4] Guangdong Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Guangzhou, Peoples R China
[5] Dalhousie Med, IMPART Investigator Team, St John, NB, Canada
[6] Univ Guelph, Dept Biomed Sci, Guelph, ON, Canada
[7] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Shanghai, Peoples R China
[8] York Univ, Dept Biol, Toronto, ON, Canada
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
n-3; PUFA; IR injury; cardioprotection; APLNR; intracellular phosphorylation signaling; ACTIVATED PROTEIN-KINASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; COUPLED RECEPTORS; APJ; LIGAND; TARGET; INJURY; ORPHAN; PATHOPHYSIOLOGY;
D O I
10.3389/fphar.2023.1145413
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: While the protective effects of n-3 polyunsaturated fatty acids (PUFAs) on cardiac ischemia-reperfusion (IR) injury have been previously reported, limited data are available regarding how these fatty acids affect membrane receptors and their downstream signaling following IR injury. We aimed to identify potential receptors activated by n-3 PUFAs in IR hearts to understand the regulatory mechanisms of these receptors.Methods: We used fat-1 mice, which naturally have elevated levels of n-3 PUFAs, and C57BL/6J mice as a control group to create a myocardial IR injury model through Langendorff perfusion. We assessed the impact of endogenous n-3 PUFAs on left ventricular function, myocardial infarct size, myocardial apoptosis, and ATP production. RNA sequencing (RNA-seq) and bioinformatics analysis were conducted to identify molecular targets affected by n-3 PUFAs. Based on these analyses we then treated IR hearts of WT and fat-1 mice with an antagonist (ML221) or an agonist (apelin-13) for the predicted receptor to assess cardiac contractile function and intracellular signaling pathways. An in vitro hypoxia-reoxygenation (HR) model was also used to confirm the effects of n-3 PUFAs on the examined intracellular signaling pathways.Results: Endogenous n-3 PUFAs protected cardiac structure and function in post-IR hearts, and modulated phosphorylation patterns in the PI3K-AKT-mTOR signaling pathways. RNA-seq analysis revealed that n-3 PUFAs affected multiple biological processes as well as levels of the apelin receptor (APLNR). Consistent with a role for the PLNNR, ML221 synchronized the activation of the PI3K-AKT-mTOR signaling axis, suppressed the expression of PKC delta and phosphorylated p38 alpha, upregulated PKC epsilon expression, upregulated or restored the phosphorylation of myofilaments, and prevented myocardial injury and contractile dysfunction in WT IR hearts. By contrast, apelin-13 disrupted the PI3K-AKT-mTOR signaling axis in post-IR fat-1 hearts. The phosphorylation signaling targeted by APLNR inhibition in post-IR fat-1 hearts was also observed after treating HR cells with eicosatetraenoic acid (EPA).Conclusion: Endogenous n-3 PUFAs protect against post-IR injury and preserve cardiac contractile function possibly through APLNR inhibition. This inhibition synchronizes the PI3K-AKT-mTOR axis, suppresses detrimental phosphorylation signaling, and restores or increases myofilament phosphorylation in post-IR hearts. The beneficial effects observed in fat-1 transgenic mouse hearts can be attributed, at least in part, to elevated EPA levels. This study is the first to demonstrate that n-3 PUFAs protect hearts against IR injury through APLNR inhibition.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] n-3 polyunsaturated fatty acids to heal the broken heart
    Grenon, Sophie Marlene
    Conte, Michael S.
    CLINICAL LIPIDOLOGY, 2013, 8 (05) : 497 - 500
  • [42] Therapeutic potential of n-3 polyunsaturated fatty acids in disease
    Fetterman, James W., Jr.
    Zdanowicz, Martin M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (13) : 1169 - 1179
  • [43] n-3 Polyunsaturated fatty acids and mast cell activation
    Wang, Xiaofeng
    Kulka, Marianna
    JOURNAL OF LEUKOCYTE BIOLOGY, 2015, 97 (05) : 859 - 871
  • [44] N-3 Polyunsaturated Fatty Acids, Body Fat and Inflammation
    Lund, Anne-Sofie Q.
    Hasselbalch, Ann Louise
    Gamborg, Michael
    Skogstrand, Kristin
    Hougaard, David M.
    Heitmann, Berit L.
    Kyvik, Kirsten O.
    Sorensen, Thorkild I. A.
    Jess, Tine
    OBESITY FACTS, 2013, 6 (04) : 369 - 379
  • [45] n-3 Polyunsaturated fatty acids and human cytokine synthesis
    Endres, S
    LIPIDS, 1996, 31 : S239 - S242
  • [46] n-3 Polyunsaturated Fatty Acids and Their Role in Cancer Chemoprevention
    Gu Z.
    Shan K.
    Chen H.
    Chen Y.Q.
    Current Pharmacology Reports, 2015, 1 (5) : 283 - 294
  • [47] Ingestion of n-3 polyunsaturated fatty acids and ovulation in rats
    Trujillo, EP
    Broughton, KS
    JOURNAL OF REPRODUCTION AND FERTILITY, 1995, 105 (02): : 197 - 203
  • [48] n-3 polyunsaturated fatty acids supplementation in psoriasis: a review
    Mari N.L.
    Simão A.N.C.
    Dichi I.
    Nutrire, 42 (1)
  • [49] n-3 Polyunsaturated fatty acids and atopy in Korean preschoolers
    Hwang, Inkyung
    Cha, Aeri
    Lee, Hyosun
    Yoon, Hyejung
    Yoon, Taeho
    Cho, Byungmann
    Lee, Suill
    Park, Yongsoon
    LIPIDS, 2007, 42 (04) : 345 - 349
  • [50] N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia
    Vecka, Marek
    Dusejovska, Magdalena
    Stankova, Barbora
    Zeman, Miroslav
    Vavrova, Lucie
    Kodydkova, Jana
    Slaby, Adolf
    Zak, Ales
    NEUROENDOCRINOLOGY LETTERS, 2012, 33 : 87 - 92